Virus therapy targets superbug in transplant patients

NCT ID NCT06938867

Recruiting now Disease control Sponsor: SNIPR Biome Aps. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called SNIPR001, which uses specially designed viruses to kill a type of antibiotic-resistant E. coli bacteria. The trial includes 24 adults with blood cancer who are scheduled for a stem cell transplant and already carry these resistant bacteria. Participants will receive either SNIPR001 or a placebo alongside standard antibiotics to see if it is safe and can reduce the bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SNIPR001 (a mixture of viruses that target E. coli bacteria)
What this could lead to: If it works, this could help prevent dangerous E. coli infections in stem cell transplant patients who carry resistant bacteria.
What could go wrong: This is a very early, small trial with only 24 participants. The treatment may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENIC TRANSPLANT PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

escherichia coli infection hematopoietic and lymphoid cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENIC TRANSPLANT PATIENTS E COLI INFECTIONS

Contacts and locations

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
John Hopkins University
RECRUITING

Baltimore, Maryland, 21218, United States
UPMC
RECRUITING

Pittsburgh, Pennsylvania, 15213-2582, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94118, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Weill Cornell Medicine
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.